CGRPs

Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Setback at Lundbeck: CGRP migraine drug Vyepti hits expansion snag, but sales still doubled
Fierce Pharma
Lundbeck
earnings
migraines
CGRPs
Vyepti
Flag link:
The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B
The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B
Endpoints
Lundbeck
eptinezumab
migraines
CGRPs
Vyepti
Flag link:
Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst
Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst
Fierce Pharma
Allergan
Botox
migraines
physicians
neurologists
CGRPs
Flag link:
Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds?
Teva's Ajovy finally gets its autoinjector nod. Can it close the gap with Amgen, Lilly meds?
Fierce Pharma
Teva Pharmaceutical
Ajovy
migraines
autoinjectors
FDA
CGRPs
Flag link:
Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch
Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch
Fierce Pharma
Allergan
UIbrelvy
ubrogepant
FDA
migraines
CGRPs
Flag link:
Amgen's Aimovig, under fire from Lilly, loses grip on CGRP share
Amgen's Aimovig, under fire from Lilly, loses grip on CGRP share
Fierce Pharma
Amgen
CGRPs
Aimovig
migraines
Eli Lilly
Emgality
Flag link:
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK
Endpoints
Amgen
Novartis
migraines
CGRPs
Aimovig
Flag link:
The Pharma Industry Thinks It Finally Has a Fix for Migraines
The Pharma Industry Thinks It Finally Has a Fix for Migraines
Yahoo/Bloomberg
migraines
Teva Pharmaceutical
Amgen
Eli Lilly
Alder Biopharma
CGRPs
Flag link: